Sunshine Biopharma (Sunshine Biopharma) Additional Paid-In Capital : $89.84 Mil(As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Sunshine Biopharma Additional Paid-In Capital?

Sunshine Biopharma's quarterly additional paid-in capital stayed the same from Sep. 2023 ($84.39 Mil) to Dec. 2023 ($84.39 Mil) but then increased from Dec. 2023 ($84.39 Mil) to Mar. 2024 ($89.84 Mil).

Sunshine Biopharma's annual additional paid-in capital increased from Dec. 2021 ($32.79 Mil) to Dec. 2022 ($80.84 Mil) and increased from Dec. 2022 ($80.84 Mil) to Dec. 2023 ($84.39 Mil).

Sunshine Biopharma Additional Paid-In Capital Historical Data

The historical data trend for Sunshine Biopharma's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunshine Biopharma Additional Paid-In Capital Chart

Sunshine Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

16.62

19.17

32.79

80.84

84.39

Sunshine Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															80.34	84.42	84.39	84.39	89.84

Sunshine Biopharma Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Sunshine Biopharma Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Sunshine Biopharma's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Sunshine Biopharma (Sunshine Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sunshine Biopharma Inc (NAS:SBFMW) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

SBFM:USA

Address

6500 Trans-Canada Highway, 4th Floor, Pointe-Claire, QC, CAN, H9R 0A5

Website

https://www.sunshinebiopharma.com

Sunshine Biopharma Inc is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, it is engaged in the development and commercialization of science-based nutritional supplements. The company is focusing on the development of the licensed Adva-27a anticancer drug, a small molecule that has been shown to be exceptionally effective at destroying Multidrug-Resistant Cancer Cells, including Pancreatic Cancer cells (Panc-1), Small-Cell Lung Cancer cells (H69AR), Breast Cancer cells (MCF-7/MDR) and Uterine Sarcoma cells (MES-SA/Dx5).